HBL Hadasit Bio Holdings Ltd
TASE:HDST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
HBL Hadasit Bio Holdings Ltd
Net Income (Common)
HBL Hadasit Bio Holdings Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HBL Hadasit Bio Holdings Ltd
TASE:HDST
|
Net Income (Common)
-₪30.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$20.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$153.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$11.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Net Income (Common)
-$26.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
|
HBL Hadasit Bio Holdings Ltd
Glance View
HBL- Hadasit Bio-Holdings Ltd. engages in investments in research and development companies in the medical and biotechnology sectors. The Company’s subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The firm together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Company’s framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.
See Also
What is HBL Hadasit Bio Holdings Ltd's Net Income (Common)?
Net Income (Common)
-30.7m
ILS
Based on the financial report for Dec 31, 2022, HBL Hadasit Bio Holdings Ltd's Net Income (Common) amounts to -30.7m ILS.
What is HBL Hadasit Bio Holdings Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-11%
The average annual Net Income (Common) growth rates for HBL Hadasit Bio Holdings Ltd have been -11% over the past three years .
